Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Free Report) was down 3.5% on Thursday . The stock traded as low as $13.55 and last traded at $13.80. Approximately 11,686 shares traded hands during trading, an increase of 372% from the average daily volume of 2,477 shares. The stock had previously closed at $14.30.
Finch Therapeutics Group Trading Down 1.1%
The stock has a market capitalization of $21.98 million, a price-to-earnings ratio of -1.55 and a beta of 1.17. The stock has a fifty day moving average of $12.87 and a two-hundred day moving average of $12.91.
Finch Therapeutics Group Company Profile
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
Featured Articles
- Five stocks we like better than Finch Therapeutics Group
- Insider Trades May Not Tell You What You Think
- MP Materials Stock Soared After Earnings—Here’s the Real Reason
- What Is WallStreetBets and What Stocks Are They Targeting?
- Why Palantir Slide May Be a Setup for a Long-Term Opportunity
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Attention Income Investors: This REIT Is on Sale
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.
